Evidence map›Paper›PMID 8941637›Full record

ArticleThe Journal of clinical investigation1996

Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.

N Ashizawa, K Graf, Y S Do, T Nunohiro, C M Giachelli, W P Meehan, T L Tuan, W A Hsueh

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 249 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Cardiac fibrosis.Cardiovascular research · 2021
    Review
  15. Review
  16. Review
  17. Targeting the renin-angiotensin-aldosterone system in fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2020
    Review
  18. Article
  19. Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.Journal of the American College of Cardiology · 2020
    Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

N AshizawaUniversity of Southern California School of Medicine, Department of Medicine, Los Angeles 90033, USA.
K Graf
Y S Do
T Nunohiro
C M Giachelli
W P Meehan
T L Tuan
W A Hsueh
University of Southern California · USSouthern California University for Professional Studies · USCentre Virchow-Villermé · FRUniversity of Washington · US

Funding

VLA-4 and VCAM-1 in Advanced AtherosclerosisP01HL018645 · NHLBI · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 1985 to 2010
$23.9M
ROLE OF THE TUBULOINTERSTITIUM IN SALT-DEPENDENT HYPERTENSIONP50DK047659 · NIDDK · UNIVERSITY OF WASHINGTON · PI ROBERTS, JAMES J · 1993 to 2002
$2.2M
PPARGAMMA AND AII IN GLOMERULOSCLEROSISR01DK030254 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HSUEH, WILLA A. · 1986 to 2002
$1.2M
NHLBI NIH HHS HL18645NIDDK NIH HHS 5R01-DK30254NIDDK NIH HHS DK47659
6 · The paper itself

Abstract

Angiotensin II (AII) is a critical factor in cardiac remodeling which involves hypertrophy, fibroblast proliferation, and extracellular matrix production. However, little is known about the mechanism by which AII accelerates these responses. Osteopontin is an acidic phosphoprotein with RGD (arginine-glycine-aspartate) sequences that are involved in the vascular smooth muscle cell remodeling process. We identified the presence of osteopontin mRNA and protein in cultured rat cardiac fibroblasts and its prominent regulation by AII (10(-11) M). Osteopontin message levels were increased fourfold (P < 0.01) and protein fivefold (P < 0.05) at 24 h after addition of AII (10(-7) M). This response was inhibited by the AT1 receptor blocker, losartan. Osteopontin mRNA levels were increased in hypertrophied ventricles from animals with renovascular hypertension (1.6-fold, P < 0.05) and aortic banding (2.9-fold, P < 0.05). To examine the function of osteopontin, we determined its effects on (a) the ability of cardiac fibroblasts to contract three-dimensional collagen gels and (b) cardiac fibroblast growth. A monoclonal antibody against osteopontin partially blocked AII-induced three-dimensional collagen gel contraction by cardiac fibroblasts (64+/-4 vs. 86+/-5% in the presence of antibody, P < 0.05), while osteopontin itself promoted contraction of the gels by fibroblasts (71+/-5%, P < 0.05 compared with control). Either a monoclonal antibody against beta3 integrin which is a ligand for osteopontin or the RGD peptide blocked both AII and osteopontin-induced collagen gel contraction. Thus, the osteopontin RGD sequence binds to beta3 integrins on the fibroblast to promote fibroblast binding to collagen. All induced a threefold increase in DNA synthesis of cardiac fibroblasts, which was completely blocked by antibodies against osteopontin and beta3 integrin, or by RGD peptide, but not by controls. Thus, All-induced growth of cardiac fibroblasts also requires osteopontin engagement of the beta3 integrin. Taken together, these results provide the first evidence that osteopontin is a potentially important mediator of AII regulation of cardiac fibroblast behavior in the cardiac remodeling process.

Indexed as

Wound HealingAngiotensin IIAnimalsAntibodies, BlockingAntibodies, MonoclonalBiphenyl CompoundsBlotting, NorthernCells, CulturedCollagenDNAFibroblastsHypertension, RenovascularHypertrophy, Left VentricularImidazolesImmunohistochemistryIntegrinsAngiotensin IIAntibodies, BlockingAntibodies, Monoclonalarginyl-glycyl-aspartic acidBiphenyl CompoundsCollagenDNAImidazolesIntegrinsLosartanOligopeptidesOsteopontinProteinsRNA, MessengerSialoglycoproteinsSpp1 protein, ratTetrazoles

Identifiers

PMID8941637
PMCPMC507670
OpenAlexW2022852324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.